Saving changes...

Done

Error

Using Concentrated Insulins: A New Strategy for the Insulin-resistant Patient

Using Concentrated Insulins: A New Strategy for the Insulin-resistant Patient

Using Concentrated Insulins: A New Strategy for the Insulin-resistant Patient

National Association for Continuing Education
National Association for Continuing Education
on behalf of National Association for Continuing Education

$20.00 $ 20.00 $ 20.00

$20.00 $ 20.00 $ 20.00

$ 20.00 $ 20.00 $ 20.00
$ 20.00 $ 20.00 $ 20.00
Normal Price: $20.00 $20.00

Review:

Launch date: 15 Feb 2018
Expiry Date: 14 Jan 2019

Last updated: 22 Aug 2018

Reference: 187003

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Welcome to the National Association for Continuing Education monograph from the
NACE Clinical Updates for NPs and PAs 2017 conference.

The global epidemic of obesity is contributing to an increasing prevalence of T2DM. This obesity is also associated with increasing insulin resistance, necessitating the use of higher insulin doses for achieving/maintaining glycemic control. Due to progressive β-cell dysfunction in T2DM, oral drugs such as metformin are often inadequate for achieving/maintaining glycemic control, and hence most patients will need insulin therapy for managing their disease, with early initiation being recommended for better outcomes. New preparations of concentrated, and long acting, insulins are available and may be appropriate for use in these situations. However, many clinicians are not familiar with these newer preparations and how to confidently utilize them.This educational program will discuss the differences between the available concentrated insulins, including their pharmacokinetic/pharmacodynamic profiles and other considerations for their use including the need for good provider-patient communication and proper patient education, which is particularly important to minimize dosing errors.

Objectives

Objective 1: Describe the role of insulin therapy in patients with T2DM not meeting glycemic goals.
After completing this program participants should be able to describe the role of insulin therapy in patients with T2DM not meeting glycemic goals.
Objective 2: Discuss the need for concentrated insulins in T2DM management.
After completing this program participants should be able to discuss the need for concentrated insulins in T2DM management.
Objective 3: Discuss the pharmacokinetic/pharmacodynamic profiles and other considerations for the use of concentrated insulin preparations.
After completing this program participants should be able to discuss the pharmacokinetic/pharmacodynamic profiles and other considerations for the use of concentrated insulin preparations.
Objective 4: Recognize the need for counseling patients about concentrated insulins to minimize dosing errors.
After completing this program participants should be able to recognize the need for counseling patients about concentrated insulins to minimize dosing errors.
National Association for Continuing Education

Author Information Play Video Bio

National Association for Continuing Education
on behalf of National Association for Continuing Education

The mission of the National Association for Continuing Education (NACE) is to offer continuing education opportunities to provide learners in the fields of medicine, behavioral health, education, and related disciplines, with the most up-to-date, science-based information that will enable them to increase their knowledge, competence, and professional performance to ultimately benefit their patients' health.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • American Association of Nurse Practitioners (AANP)
  • 1.00 Hours -
    Exam Pass Rate: 70

Faculty and Disclosures

Additional Contributors

Course Directors
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Deborah Paschal, CRNP
Philadelphia, PA

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Course Reviewer
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC
Director, Riverside Diabetes Center
Riverside Medical Associates
Adjunct Assistant Professor
Uniformed Services
University of the Health Sciences
Bethesda, MD

Conflicts Declared

Conflicts of Interest declaration by Author:

Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Lucia Novak, MSN, ANP-BC, BC-ADM, CDTC is a speaker for Janssen Pharmaceuticals, Inc, Novo Nordisk, Inc and AstraZeneca Pharmaceuticals LP. Ms. Novak is a member on the Advisory Committee for Sanofi.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Deborah Paschal, CRNP, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

This educational activity is supported by an an educational grant from Sanofi US.

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error